Risk and Management of Patients with Cancer and Heart Disease
Journal
Cardiology and therapy
Date Issued
June 2023
DOI
10.1007/s40119-023-00305-w
Abstract
Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient's myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients' functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.
File(s)![Thumbnail Image]()
Name
lambrinou 1.pdf
Size
830.83 KB
Format
Adobe PDF
Checksum (MD5)
b54199d4dcf59f07af7a58779de57524